Rubicon Research IPO: Price Band, GMP, Allotment, Listing Date
Rubicon Research Ltd is set to enter the primary market with its much-awaited initial public offering opening on October 9, 2025, and closing on October 13, 2025. The Mumbai-based pharmaceutical company Rubicon Research IPO aims to raise approximately ₹1,377.50 crores through this IPO, consisting of a fresh issue of ₹500 crores and an offer for sale (OFS) of up to 1.80 crore equity shares with a face value of ₹1 each. This IPO is structured as a Book Built Issue, and the equity shares are proposed to be listed on both the BSE and NSE. The IPO aims to fund debt repayment, support inorganic expansion, and meet general corporate needs.
The price band for the Rubicon Research IPO is set between ₹461 and ₹485 per share, and the shares will carry a face value of ₹1 each. The IPO will list on both BSE and National Stock Exchange (NSE) on October 16, 2025. Investors can look forward to the basis of allotment being finalized on October 14, 2025.
Rubicon Research has a revenue of ₹1,296.22 crore in FY2025, up from ₹872.39 crore in FY2024, and a net profit increase to ₹134.36 crore. These financials numbers reflect the company’s expanding presence in the global pharma industry and long-term growth prospects.
Rubicon Research IPO Details
| Particular | Details |
|---|---|
| IPO Open Date | October 9, 2025 |
| IPO Close Date | October 13, 2025 |
| Face Value | ₹1 per equity share |
| IPO Price Band | ₹461 to ₹485 per share |
| Issue Size | Approx ₹1,377.50 crore |
| Fresh Issue | Approx ₹500 crore |
| Offer for Sale | 1,80,92,762 equity shares |
| Issue Type | Book Built Issue |
| Listing At | BSE, NSE |
| Basis of Allotment | October 14, 2025 |
| Credit to Demat | October 15, 2025 |
| Basis of Allotment | October 14, 2025 |
| Listing Date | October 16, 2025 |
Rubicon Research IPO Market Lot Size
| Application | Lot Size | Shares | Amount (₹) |
|---|---|---|---|
| Retail Minimum | 1 | 30 | ₹14,550 |
| Retail Maximum | 13 | 390 | ₹1,89,150 |
| S-HNI Minimum | 14 | 420 | ₹2,03,700 |
| S-HNI Maximum | 68 | 2,040 | ₹9,89,400 |
| B-HNI Minimum | 69 | 2,070 | ₹10,03,950 |
The minimum application size for retail investors is 30 shares, amounting to ₹14,550, while the maximum for retail is 13 lots (390 shares) totaling ₹1,89,150. For high net-worth investors, the Small HNI (S-HNI) category begins at 14 lots (420 shares) with an investment of approximately ₹2,03,700, while Big HNI (B-HNI) applications start at 69 lots (2,070 shares) worth about ₹10,03,950. This flexible lot structure allows investors across categories to participate according to their investment capacity and portfolio strategy.
Rubicon Research IPO Reservation
| Investor Category | Shares Offered | % of Issue |
|---|---|---|
| QIB (Including Anchor) | – | 75% |
| NII (HNI) | – | 15% |
| Retail | – | 10% |
Rubicon Research IPO Allotment & Listing
The allotment for the Rubicon Research IPO will be finalized on October 14, 2025, with refunds initiated on October 15, 2025. The credited shares will appear in investors’ Demat accounts by the same day, and trading will commence on October 16, 2025.
About Rubicon Research Ltd
Rubicon Research Ltd is a pharmaceutical company specializing in product development and drug delivery solutions. The company operates in multiple segments including formulation development, licensing, manufacturing, and global distribution. With robust R&D capabilities and a strong pipeline of products across therapeutic areas, Rubicon serves clients in regulated markets like the US, Europe, and India.
Disclaimer: This article is for educational and informational purposes only and should not be considered investment advice. Investors should conduct their own research and read and understand all official company documents, including the DRHP/RHP, with the assistance of a legally registered and certified financial professional before making any investment decisions. Any opinions or reviews expressed in this article are for informational purposes only and do not constitute a recommendation to buy or sell securities.
